No Data
Altimmune's Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Altimmune's Pemvidutide: A Promising Best-in-Class Therapy With Broad Potential and Strong Buy Rating
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Key Deals This Week: ServiceNow, Eaton, Crown Castle, Victoria's Secret and More
